vs
Side-by-side financial comparison of International General Insurance Holdings Ltd. (IGIC) and QuidelOrtho Corp (QDEL). Click either name above to swap in a different company.
QuidelOrtho Corp is the larger business by last-quarter revenue ($619.8M vs $403.8M, roughly 1.5× International General Insurance Holdings Ltd.). International General Insurance Holdings Ltd. runs the higher net margin — 26.0% vs -14.8%, a 40.8% gap on every dollar of revenue.
China Taiping Insurance Holdings Company Limited (CTIH) formerly China Insurance International Holdings Company Limited (CIIH), is a Chinese insurance conglomerate. The company has strong Chinese Central Government background despite being incorporated in Hong Kong. It is considered as a red chip company.
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.
IGIC vs QDEL — Head-to-Head
Income Statement — Q3 FY2025 vs Q1 FY2027
| Metric | | |
|---|---|---|
| Revenue | $403.8M | $619.8M |
| Net Profit | $105.1M | $-91.8M |
| Gross Margin | — | — |
| Operating Margin | — | — |
| Net Margin | 26.0% | -14.8% |
| Revenue YoY | — | -10.5% |
| Net Profit YoY | — | — |
| EPS (diluted) | $2.31 | $-1.35 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $619.8M | ||
| Q3 25 | $403.8M | $699.9M | ||
| Q2 25 | $261.9M | $613.9M | ||
| Q1 25 | — | $692.8M | ||
| Q4 24 | — | $707.8M | ||
| Q3 24 | $369.6M | $727.1M | ||
| Q2 24 | $265.8M | $637.0M | ||
| Q1 24 | — | $711.0M |
| Q1 26 | — | $-91.8M | ||
| Q3 25 | $105.1M | $-733.0M | ||
| Q2 25 | $61.4M | $-255.4M | ||
| Q1 25 | — | $-12.7M | ||
| Q4 24 | — | $-178.4M | ||
| Q3 24 | $-134.4M | $-19.9M | ||
| Q2 24 | $70.7M | $-147.7M | ||
| Q1 24 | — | $-1.7B |
| Q1 26 | — | — | ||
| Q3 25 | — | -100.7% | ||
| Q2 25 | 24.2% | -29.4% | ||
| Q1 25 | — | 4.7% | ||
| Q4 24 | — | -14.2% | ||
| Q3 24 | — | 2.1% | ||
| Q2 24 | -73.3% | -18.4% | ||
| Q1 24 | — | -247.3% |
| Q1 26 | — | -14.8% | ||
| Q3 25 | 26.0% | -104.7% | ||
| Q2 25 | 23.5% | -41.6% | ||
| Q1 25 | — | -1.8% | ||
| Q4 24 | — | -25.2% | ||
| Q3 24 | -36.4% | -2.7% | ||
| Q2 24 | 26.6% | -23.2% | ||
| Q1 24 | — | -239.9% |
| Q1 26 | — | $-1.35 | ||
| Q3 25 | $2.31 | $-10.78 | ||
| Q2 25 | $1.36 | $-3.77 | ||
| Q1 25 | — | $-0.19 | ||
| Q4 24 | — | $-2.54 | ||
| Q3 24 | $1.82 | $-0.30 | ||
| Q2 24 | $1.55 | $-2.20 | ||
| Q1 24 | — | $-25.50 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $244.7M | $140.4M |
| Total DebtLower is stronger | — | $2.5B |
| Stockholders' EquityBook value | $654.8M | $1.9B |
| Total Assets | $2.0B | $5.6B |
| Debt / EquityLower = less leverage | — | 1.33× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $140.4M | ||
| Q3 25 | $244.7M | $98.1M | ||
| Q2 25 | $164.8M | $151.7M | ||
| Q1 25 | — | $127.1M | ||
| Q4 24 | — | $98.3M | ||
| Q3 24 | $219.2M | $143.7M | ||
| Q2 24 | $237.3M | $107.0M | ||
| Q1 24 | — | $78.5M |
| Q1 26 | — | $2.5B | ||
| Q3 25 | — | $2.5B | ||
| Q2 25 | — | $2.1B | ||
| Q1 25 | — | $2.1B | ||
| Q4 24 | — | $2.1B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $2.2B | ||
| Q1 24 | — | $2.2B |
| Q1 26 | — | $1.9B | ||
| Q3 25 | $654.8M | $2.0B | ||
| Q2 25 | $662.3M | $2.8B | ||
| Q1 25 | — | $3.0B | ||
| Q4 24 | — | $3.0B | ||
| Q3 24 | $540.5M | $3.2B | ||
| Q2 24 | $588.2M | $3.2B | ||
| Q1 24 | — | $3.3B |
| Q1 26 | — | $5.6B | ||
| Q3 25 | $2.0B | $5.7B | ||
| Q2 25 | $2.1B | $6.4B | ||
| Q1 25 | — | $6.5B | ||
| Q4 24 | — | $6.4B | ||
| Q3 24 | $1.8B | $6.8B | ||
| Q2 24 | $2.0B | $6.7B | ||
| Q1 24 | — | $6.7B |
| Q1 26 | — | 1.33× | ||
| Q3 25 | — | 1.23× | ||
| Q2 25 | — | 0.74× | ||
| Q1 25 | — | 0.70× | ||
| Q4 24 | — | 0.72× | ||
| Q3 24 | — | 0.68× | ||
| Q2 24 | — | 0.70× | ||
| Q1 24 | — | 0.68× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IGIC
Segment breakdown not available.
QDEL
| Labs | $353.1M | 57% |
| Immunohematology | $138.3M | 22% |
| Point of Care | $112.8M | 18% |
| Molecular Diagnostics | $7.8M | 1% |
